What non‑opioid medications can be prescribed for bladder or pelvic pain?

Non-Opioid Pain Medications for Bladder/Pelvic Pain

For bladder/pelvic pain, prescribe amitriptyline as first-line oral therapy starting at 10 mg nightly and titrate gradually to 75-100 mg as tolerated, with NSAIDs (such as celecoxib) and phenazopyridine for short-term adjunctive relief. 1, 2

First-Line Oral Medications

Amitriptyline (Strongest Evidence)

• Start at 10 mg nightly and titrate gradually to 75-100 mg if tolerated 2
• Superior to placebo for IC/BPS symptom improvement (Grade B evidence) 2
• Should be first treatment offered based on systematic review 3
• Common side effects include sedation, drowsiness, and nausea—substantial but not life-threatening 2
• Works even without documented depression history (only 56% of IC/BPS patients prescribed amitriptyline had depression) 4

NSAIDs and COX-2 Inhibitors

• Celecoxib showed significant reduction in pain and quality of life scores in category IIIA prostatitis 1
• Anti-inflammatory agents have pooled relative risk of 1.8 (95% CI: 1.2-2.6) for pain reduction 1
• Use as part of multimodal pain management strategy 1
• Greater improvement in patients with higher baseline pain scores 1

Second-Line Options

Hydroxyzine

• Dose: Standard antihistamine dosing
• Clinically significant improvement compared to placebo (Grade C evidence) 2
• Patients with systemic allergies may respond better 2
• Prescription prevalence increased from 17% to 40% after IC/BPS diagnosis 4
• Common side effects: short-term sedation and weakness 2

Cimetidine

• Clinically significant improvement in IC/BPS symptoms, pain, and nocturia 2
• No adverse events reported (Grade B evidence) 2
• Underutilized option with favorable safety profile

Pentosan Polysulfate (PPS)

• Only FDA-approved oral agent for IC/BPS 2
• Prescription increased from 10% to 29% after diagnosis 4
• CRITICAL CAVEAT: Must counsel patients on potential risk for macular damage and vision-related injuries before initiating 2
• Many patients now choose not to start or discontinue due to pigmented maculopathy concerns 5
• Contradictory effectiveness data—some trials show no difference, others show improvement 2

Short-Term Adjunctive Therapy

Phenazopyridine (Urinary Analgesic)

• Dose: 100-200 mg three times daily 1
• Reduce to 100 mg twice daily for mild renal insufficiency 1
• Works as urinary tract analgesic for dysuria relief 1
• No evidence of effectiveness beyond 15 days 1
• Contraindications: Significant renal insufficiency (<50 mL/min) and liver failure 1

Acetaminophen

• Safe up to 4 g/day in adults 1
• Doses above recommended may lead to hepatotoxicity and death 1
• Can be used empirically as for any chronic pain state 1

Critical Implementation Principles

Titration Strategy:

• Start with smallest available dose 1
• Titrate only ONE drug at a time to assess individual effects 1
• Titrate at frequent intervals guided by pain scores and side effects 1

Realistic Expectations:

• Goal is to improve quality of life and daily functioning, not necessarily eliminate pain 1
• Pain management alone is insufficient—multimodal approach combining pharmacologic agents with other therapies (pelvic floor physical therapy, behavioral modifications, stress management) is most effective 2, 6

Common Pitfall to Avoid:

• Do not prescribe opioids for chronic bladder/pelvic pain—refer to dedicated pain physicians given complexity of assessment 1
• Non-opioid alternatives should be used preferentially 2

Evidence Quality Note

The 2025 AUA guideline on male chronic pelvic pain 1 and 2022 AUA guideline on IC/BPS 2 provide the strongest framework. Notably, 44% of IC/BPS patients required three or more pain medications, highlighting treatment difficulty 4. The shift toward recognizing chronic pelvic pain as a whole-person condition rather than organ-focused pathology supports this multimodal approach 6.